For patients who already have flow cytometry, can you just run the drug sensitivity profile?

Yes, our AI-driven Drug Response Predictions Only (DRP) service is available starting May 2024. This service focuses solely on the drug prediction aspect, providing you with insights without the flow cytometry and PARR results.

Other Questions

Back to Help Center

Can the test be used on cats and other animals?

At this time, we only offer commercial services to canine lymphoma patients. However, we are conducting research into feline lymphoma so if you would like to submit a sample please sign up here if you are interested in feline services.

Can the testing be performed on dogs that are currently on therapy?

Current therapy will not affect our AI predictions or immunoprofile results. However, reduction of tumor size caused by therapy may increase the likelihood of service failure due to insufficient cells. In the event of service failure, you will not be billed.

How does ImpriMed predict drug responses?

Our predictions are made by artificial intelligence (AI) models trained to predict clinical outcomes from patient data inputs. Clinical outcomes collected from oncologists include reports of progressive disease, stable disease, partial response, and complete response. Patient data used as inputs by the AI models include readings from our live-cell drug sensitivity assay, flow cytometry, PARR, and patient information.Models are re-trained periodically to incorporate new data and refine performance.

How do vets report back the outcomes to feed back into the AI model? Is this something that can be easily done via the Vet portal?

We usually send you an email asking for patient records about 3-6 months after you receive the final ImpriMed report. Once we receive the record, we input the data into the AI Models, it is not yet something that can be submitted on the Vet Portal.

How much research do you have to support your results?

All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.